Chemical Compound
14,15-Dehydro Budesonide
CAS Registry Number
131918-64-4
Primary Record
14,15-Dehydro Budesonide
- In stock
- 2,053 g
- Purity
- 98.1 %
- CAS
- 131918-64-4
Compound Identifiers & Properties
- CAS
- 131918-64-4
- PubChem CID
- 12989325
- SMILES
- CCCC1O[C@@H]2C=C3[C@@H]4CCC5=CC(=O)C=C[C@@]5([C@H]4[C@H](C[C@@]3([C@@]2(O1)C(=O)CO)C)O)C
- Canonical SMILES
- CCCC1O[C@@H]2C=C3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
Names & Synonyms
- 14,15-Dehydro Budesonide
- Budesonide 14-ene
- UGU7BPL6BD
- 14,15-Dehydrobudesonide
- Budesonide EP Impurity E
- 131918-64-4
- UNII-UGU7BPL6BD
- RefChem:1057493
- Budesonide Related Compound E
- Budesonide related compound E [USP]
- DTXSID10514461
- C25H32O6
- MFCD29472410
- FD20897
- SY058240
- BUDESONIDE IMPURITY E [EP IMPURITY]
- CS-0166431
- J1.024.068I
- BUDESONIDE RELATED COMPOUND E [USP-RS]
- G76541
- F988302
- (1R,4R,8S,9S,11S,12S,13R)-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-propyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-2,14,17-trien-16-one
- BUDESONIDE RELATED COMPOUND E [USP IMPURITY]
- (11beta,16alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4,14-triene-3,20-dione
- 16alpha,17-(Butylidenebis(oxy))-11beta,21-dihydroxypregna-1,4,14-triene-3,20-dione
- (6AR,6BS,7S,8AS,8BS,11AR,12BR)-7-HYDROXY-8B-(2-HYDROXYACETYL)-6A,8A-DIMETHYL-10-PROPYL-6A,6B,7,8,8A,8B,11A,12B-OCTAHYDRO-1H-NAPHTHO[2',1':4,5]INDENO[1,2-D][1,3]DIOXOL-4(2H)-ONE
- Pregna-1,4,14-triene-3,20-dione, 16,17-(butylidenebis(oxy))-11,21-dihydroxy-, (11beta,16alpha)-
- (11|A,16|A)-16,17-[Butylidenebis(oxy)]-11,21-dihydroxypregna-1,4,14-triene-3,20-dione
- 11beta,21-Dihydroxy-16alpha,17-(butylidenebisoxy)pregna-1,4,14-triene-3,20-dione
- 11beta,21-Dihydroxy-16alpha,17-(butylidenedioxy)pregna-1,4,14-triene-3,20-dione
- 16?,17-[Butylidenebis(oxy)]-11?,21-dihydroxypregna-1,4,14-triene-3,20-dione
- 16alpha,17-[butylidenebis(oxy)]-11beta,21-dihydroxypregna-1,4,14-triene-3,20-dione
- 16alpha,17alpha-Butylidenebisoxy-11beta,21-dihydroxypregna-1,4,14-triene-3,20-dione
- (11.BETA.,16.ALPHA.)-16,17-(BUTYLIDENEBIS(OXY))-11,21-DIHYDROXYPREGNA-1,4,14-TRIENE-3,20-DIONE
- (11beta,16beta)-16,17-[Butylidenebis(oxy)]-11,21-dihydroxypregna-1,4,14-triene-3,20-dione
- (4aR,4bS,5S,6aS,6bS,9aR,10bR)-5-Hydroxy-6b-(hydroxyacetyl)-4a,6a-dimethyl-8-propyl-4a,4b,5,6,6a,6b,9a,10b,11,12-decahydro-2H,8H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one
- (4bS,5S,6aS,6bS,9aR,10bR)-5-Hydroxy-6b-(hydroxyacetyl)-4a,6a-dimethyl-8-propyl-4a,4b,5,6,6a,6b,9a,10b,11,12-decahydro-2H,8H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one
- (6aR,6bS,7S,8aS,8bS,11aR,12bR)-7-hydroxy-8b-(2-hydroxyacetyl)-6a,8a-dimethyl-10-propyl-1,2,6a,6b,7,8,8a,8b,11a,12b-decahydro-4H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-4-one
- (6aR,6bS,7S,8aS,8bS,11aR,12bR)-7-hydroxy-8b-(2-hydroxyacetyl)-6a,8a-dimethyl-10-propyl-6a,6b,7,8,8a,8b,11a,12b-octahydro-1H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-4(2H)-one (Budesonide Impurity
- (6aR,6bS,7S,8aS,8bS,11aR,12bR)-7-hydroxy-8b-(2-hydroxyacetyl)-6a,8a-dimethyl-10-propyl-6a,6b,7,8,8a,8b,11a,12b-octahydro-1H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-4(2H)-one(BudesonideImpurity pound(c)
- (6aR,6bS,7S,8aS,8bS,11aR,12bR)-7-hydroxy-8b-(2-hydroxyacetyl)-6a,8a-dimethyl-10-propyl-6a,6b,7,8,8a,8b,11a,12b-octahydro-1H-naphtho[2,1:4,5]indeno[1,2-d][1,3]dioxol-4(2H)-one
- 16.ALPHA.,17-(BUTYLIDENEBIS(OXY))-11.BETA.,21-DIHYDROXYPREGNA-1,4,14-TRIENE-3,20-DIONE
- 16a,17-[(1RS)-Butylidenebis(oxy)]-11ss,21-dihydroxypregna-1,4,14-triene-3,20-dione; 14,15-Didehydrobudesonide; Budesonide Imp. E (EP); Pregna-1,4,14-triene-3,20-dione, 16,17-[butylidenebis(oxy)]-11,21-dihydroxy-, (11ss,16a)-; (11ss,16a)-16,17-[Butylidenebis(oxy)]-11,21-dihydroxypregna-1,4,14-triene-3,20-dione; 2H-Naphth[2',1':4,5]indeno[1,2-d][1,3]dioxole, pregna-1,4,14-triene-3,20-dione deriv.; 16a,17-[Butylidenebis(oxy)]-11ss,21-dihydroxypregna-1,4,14-triene-3,20-dione
- PREGNA-1,4,14-TRIENE-3,20-DIONE, 16,17-(BUTYLIDENEBIS(OXY))-11,21-DIHYDROXY-, (11.BETA.,16.ALPHA.)-